参附注射液联合重组人脑利钠肽治疗急性左心衰竭102例疗效观察
发布时间：2018-12-05 21:21
【摘要】：目的观察参附注射液(去甲乌头碱和人参皂苷)联合重组人脑利钠肽(rh BNP)治疗急性左心衰竭(ALHF)疗效。方法将203例ALHF患者随机分为两组,对照组101例在常规治疗基础上静脉输注冻干rh BNP注射液,治疗组102例在对照组基础上加用参附注射液,观察两组疗效和药物副作用。结果治疗组总有效率显著高于对照组;治疗后两组血浆人脑利钠肽(BNP)水平显著降低,治疗组治疗后血浆BNP水平较对照组显著降低;两组左室射血分数(LVEF)和左室短轴缩短率(LVFS)较治疗前显著升高,左室舒张末内径(LVEDD)显著降低,治疗组治疗后LVEF和LVFS较对照组显著升高,LVEDD显著降低;治疗组治疗后血肌酐(SCr)和尿素氮(BUN)水平较治疗前显著降低,与对照组比较显著降低。治疗组低血压反应发生率低于对照组。结论参附注射液联合rh BNP治疗ALHF疗效较好,值得临床应用。
[Abstract]:Objective to observe the therapeutic effect of Shenfu injection (noraconitine and ginsenoside) combined with recombinant human brain natriuretic peptide (rh BNP) on acute left heart failure (ALHF). Methods 203 patients with ALHF were randomly divided into two groups: the control group (101 cases) received freeze-dried rh BNP injection on the basis of routine treatment, and the treatment group (102 cases) received Shenfu injection on the basis of the control group. The curative effect and side effects of the two groups were observed. Results the total effective rate in the treatment group was significantly higher than that in the control group, the plasma levels of human brain natriuretic peptide (BNP) in the two groups were significantly decreased after treatment, and the plasma BNP level in the treatment group was significantly lower than that in the control group. Left ventricular ejection fraction (LVEF), left ventricular shortening rate (LVFS) and left ventricular end-diastolic diameter (LVEDD) were significantly increased and left ventricular end-diastolic diameter (LVEDD) decreased in both groups. After treatment, LVEF and LVFS in the treatment group were significantly higher than those in the control group, and LVEDD was significantly decreased. The levels of serum creatinine (SCr) and urea nitrogen (BUN) in the treatment group were significantly lower than those before treatment and significantly lower than those in the control group. The incidence of hypotension in the treatment group was lower than that in the control group. Conclusion Shenfu injection combined with rh BNP is effective in the treatment of ALHF and is worthy of clinical application.
【作者单位】： 黄淮学院附属医院;
【分类号】：R541.6
，
本文编号：2365486
[Abstract]:Objective to observe the therapeutic effect of Shenfu injection (noraconitine and ginsenoside) combined with recombinant human brain natriuretic peptide (rh BNP) on acute left heart failure (ALHF). Methods 203 patients with ALHF were randomly divided into two groups: the control group (101 cases) received freeze-dried rh BNP injection on the basis of routine treatment, and the treatment group (102 cases) received Shenfu injection on the basis of the control group. The curative effect and side effects of the two groups were observed. Results the total effective rate in the treatment group was significantly higher than that in the control group, the plasma levels of human brain natriuretic peptide (BNP) in the two groups were significantly decreased after treatment, and the plasma BNP level in the treatment group was significantly lower than that in the control group. Left ventricular ejection fraction (LVEF), left ventricular shortening rate (LVFS) and left ventricular end-diastolic diameter (LVEDD) were significantly increased and left ventricular end-diastolic diameter (LVEDD) decreased in both groups. After treatment, LVEF and LVFS in the treatment group were significantly higher than those in the control group, and LVEDD was significantly decreased. The levels of serum creatinine (SCr) and urea nitrogen (BUN) in the treatment group were significantly lower than those before treatment and significantly lower than those in the control group. The incidence of hypotension in the treatment group was lower than that in the control group. Conclusion Shenfu injection combined with rh BNP is effective in the treatment of ALHF and is worthy of clinical application.
【作者单位】： 黄淮学院附属医院;
【分类号】：R541.6
，
本文编号：2365486
本文链接：https://www.wllwen.com/yixuelunwen/jjyx/2365486.html
最近更新
教材专著
